Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India-Reference-Cited by-同舟云学术

Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

Published:2019-08-29 Issue:8 Volume:14 Page:e0221769
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chugh Yashika,Dhiman Radha Krishan,Premkumar Madhumita,Prinja Shankar^ORCID,Singh Grover Gagandeep,Bahuguna Pankaj

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference54 articles.

1. Hepatitis C in India;A Mukhopadhya;J Biosci,2008

2. A systematic review of hepatitis C virus epidemiology in Asia;W Sievert;Australia and Egypt. Liver Int,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recompensation of Chronic Hepatitis C–Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program;Gastroenterology;2024-08

2. Cost effectiveness of hepatitis C direct acting agents;Expert Review of Pharmacoeconomics & Outcomes Research;2024-05-03

3. Peculiarities of real-world data application for health technology assessment in Asian countries;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-30

4. Universal health coverage in India and health technology assessment: current status and the way forward;Frontiers in Public Health;2023-06-02

5. Conveyance of sofosbuvir through vesicular lipid nanocarriers as an effective strategy for management of viral meningitis;RSC Advances;2023